Serina Therapeutics Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
SER
- Investments
-
1
- Share Price
-
$4.81
- (As of Friday Closing)
Serina Therapeutics General Information
Description
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
Contact Information
Website
www.serinatherapeutics.comCorporate Office
- 601 Genome Way
- Suite 2001
- Huntsville, AL 35806
- United States
Corporate Office
- 601 Genome Way
- Suite 2001
- Huntsville, AL 35806
- United States
Serina Therapeutics Timeline
Serina Therapeutics Stock Performance
As of 17-Jan-2025, Serina Therapeutics’s stock price is $4.81. Its current market cap is $45.2M with 9.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.81 | $4.75 | $3.81 - $19.93 | $45.2M | 9.4M | 27.6K | $0.56 |
Serina Therapeutics Financials Summary
As of 30-Jun-2023, Serina Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|
| Revenue | 0 | 500 | 3,039 |
| EBITDA | 1,467 | (2,607) | (1,239) |
| Net Income | 1,193 | (2,682) | (1,265) |
| Total Assets | 9,739 | 858 | 1,844 |
| Total Debt | 8,193 | 1,809 | 398 |
Serina Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Serina Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Serina Therapeutics Comparisons
Industry
Financing
Details
Serina Therapeutics Competitors (61)
One of Serina Therapeutics’s 61 competitors is Invectys, a Venture Capital-Backed company based in Houston, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Invectys | Venture Capital-Backed | Houston, TX | ||||
| Cantex Pharmaceuticals | Formerly VC-backed | Weston, FL | ||||
| PDX Pharmaceuticals | Venture Capital-Backed | Portland, OR | ||||
| CalciMedica | Formerly VC-backed | San Diego, CA | ||||
| Synthekine | Venture Capital-Backed | Menlo Park, CA |
Serina Therapeutics Patents
Serina Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250017857-A1 | Poly(oxazoline) conjugates with pendant cationic groups and lipid nanoparticles and polyplexes including same | Pending | 15-Jun-2023 | ||
| US-20240277821-A1 | Targeting of antigen-presenting cells by nanoparticles containing polyoxazoline-lipid conjugates | Pending | 20-Jan-2023 | ||
| US-20240350553-A1 | Methods for modulating the regenerative phenotype in mammalian cells | Pending | 15-Oct-2021 | ||
| AU-2022230996-A1 | Use of protocadherins in methods of diagnosing and treating cancer | Pending | 02-Mar-2021 | ||
| US-20220249695-A1 | Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same | Pending | 09-Feb-2021 | A61K47/6935 |
Serina Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Serina Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Serina Therapeutics Acquisitions (1)
Serina Therapeutics’s most recent deal was a Merger/Acquisition with AgeX Therapeutics. The deal was made on 26-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AgeX Therapeutics | 26-Mar-2024 | Merger/Acquisition | Biotechnology |
Serina Therapeutics FAQs
-
When was Serina Therapeutics founded?
Serina Therapeutics was founded in 2006.
-
Where is Serina Therapeutics headquartered?
Serina Therapeutics is headquartered in Huntsville, AL.
-
What is the size of Serina Therapeutics?
Serina Therapeutics has 10 total employees.
-
What industry is Serina Therapeutics in?
Serina Therapeutics’s primary industry is Drug Discovery.
-
Is Serina Therapeutics a private or public company?
Serina Therapeutics is a Public company.
-
What is Serina Therapeutics’s stock symbol?
The ticker symbol for Serina Therapeutics is SER.
-
What is the current stock price of Serina Therapeutics?
As of 17-Jan-2025 the stock price of Serina Therapeutics is $4.81.
-
What is the current market cap of Serina Therapeutics?
The current market capitalization of Serina Therapeutics is $45.2M.
-
Who are Serina Therapeutics’s competitors?
Invectys, Cantex Pharmaceuticals, PDX Pharmaceuticals, CalciMedica, and Synthekine are some of the 61 competitors of Serina Therapeutics.
-
What is Serina Therapeutics’s annual earnings per share (EPS)?
Serina Therapeutics’s EPS for 12 months was $0.56.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
